Real-Time Alerts
Curated alerts about competitor activities across your disease states of interest
Showing alerts vetted by our team with added implications and recommendations
Filter by Disease State
Additional Filters
Alerts
Pfizer granted priority review for new multiple myeloma therapy
High PriorityThe FDA has granted priority review for Pfizer's novel BCMA-targeted therapy for relapsed/refractory multiple myeloma. The PDUFA date is set for October 15, 2025.
Implications:
This priority review could accelerate Pfizer's entry into the multiple myeloma market with a potential approval 4 months ahead of schedule. If approved, this would be the third BCMA-targeted therapy on the market, increasing competition in this space.
Recommendations:
Consider accelerating development timelines for competing multiple myeloma assets. Prepare market access strategy to differentiate from Pfizer's offering.
AstraZeneca reports positive Phase 3 results for IL-13 inhibitor in severe asthma
Medium PriorityAstraZeneca announced positive topline results from their Phase 3 trial of their IL-13 inhibitor in severe asthma. The study met its primary endpoint of reduction in exacerbation rate.
Implications:
These results strengthen AstraZeneca's position in the severe asthma market. The data showed a 56% reduction in exacerbation rate compared to placebo, which is comparable to existing biologics in this space.
Recommendations:
Monitor for full data presentation at upcoming respiratory conferences. Consider conducting a comparative analysis against our pipeline assets in development for severe asthma.
Roche announces collaboration with biotech for novel multiple myeloma target
Medium PriorityRoche has announced a strategic collaboration with a biotech company to develop a novel target for multiple myeloma. The deal includes $40M upfront with potential milestone payments of up to $1.5B.
Implications:
This collaboration signals Roche's continued interest in expanding their presence in multiple myeloma. The novel target appears to be complementary to existing BCMA-targeted approaches.
Recommendations:
Investigate the specific target and mechanism of action. Consider similar partnership opportunities with other biotechs working on novel multiple myeloma targets.
New publication on long-term safety of IL-23 inhibitors in psoriasis
Low PriorityA new meta-analysis published in JAMA Dermatology examined the long-term safety profile of IL-23 inhibitors in moderate-to-severe plaque psoriasis, showing favorable safety outcomes over 5 years.
Implications:
This publication strengthens the overall safety profile of the IL-23 inhibitor class. The meta-analysis included data from multiple products across different manufacturers.
Recommendations:
Consider incorporating these findings into medical communications for our IL-23 inhibitor. The long-term safety data could be valuable for discussions with healthcare providers.
BMS submits sNDA for psoriasis indication expansion
Medium PriorityBristol Myers Squibb has submitted a supplemental New Drug Application (sNDA) to expand the indication of their IL-17 inhibitor to include moderate-to-severe plaque psoriasis in adolescents.
Implications:
If approved, this would be the second IL-17 inhibitor approved for adolescent psoriasis, expanding BMS's addressable market. The pediatric psoriasis market remains relatively underserved.
Recommendations:
Evaluate the potential for pediatric studies with our psoriasis assets. Consider market research to understand the size and needs of the adolescent psoriasis population.
© 2025 CI Agent. All rights reserved.